Vaxcyte, INC 10-Q quarterly reports

Vaxcyte reports a significant increase in R&D expenses for Q1 2026, driven by advancements in its PCV franchise, while maintaining a robust cash and investment balance.

Vaxcyte reports increased net losses in Q3 2025 and for the nine months ended September 30, 2025, while advancing its broad-spectrum pneumococcal conjugate vaccine (PCV) candidates and securing long-term manufacturing agreements.

Vaxcyte, a clinical-stage vaccine company, reported increased net losses in Q2 2025 while strategically advancing its lead pneumococcal conjugate vaccine candidates and streamlining its early-stage pipeline.

Vaxcyte announces positive topline results from its VAX-24 infant Phase 2 dose-finding study and progresses its VAX-31 infant Phase 2 study to the final stage.

Vaxcyte's Q3 2024 filing highlights positive clinical trial results for VAX-31, a significant capital raise, and ongoing development of its vaccine pipeline.

Vaxcyte, a clinical-stage vaccine company, reported a net loss of $128.7 million for the second quarter of 2024, while advancing its pipeline of vaccine candidates.

Vaxcyte's first quarter of 2024 saw significant financial gains from a follow-on offering and continued advancement of its clinical programs, particularly for its pneumococcal vaccine candidates.